Oliver Capel’s Post

🤝And we already have 2 more key developments in the Pharma and Digital Health partnership space this month>> 🧠Otsuka Pharmaceutical Co., Ltd. and Verily have launched "My Mental Health Journey," a longitudinal real world digital study to better understand depression, aiming to advance personalized treatments for depression 🧬Novartis and Dawn Health have launched Ekiva PNH, a digital health tool designed for managing Paroxysmal Nocturnal Hemoglobinuria (PNH). It builds on the Ekiva MS for Multiple Sclerosis tool that the pair launched last year 👇Links to related articles in comments below #DigitalHealth #Pharma

In today’s competitive therapeutic, diagnostic and medical device landscape, companies need to understand product value early on, and develop evidence to demonstrate value to all stakeholders. Market Access Consulting and Health Economics and Outcomes Research (HEOR) are more relevant than ever. Real-world evidence, patient-centered data and economic data are increasingly important to assist regulators and other stakeholders in understanding a product’s benefits, risks and value. Learn more: https://lnkd.in/gJCrmHNt #MarketAccess #Pricing #Reimbursement #HEOR

Is race a reliable indicator of drug metabolism? Doctors Brandy Gunsolus and Dana Powell Baker, Ed.D., MBA, MS, CPH, MLS(ASCP)cm explain why race-based drug corrections are outdated and can lead to misdiagnosis. Watch our new 🎥 to learn more about this important topic. ➡️https://bit.ly/3MwoFdm #medlabscience #racebasedmedicine #drugmetabolism #science #healthcare #misdiagnosis #healthliteracymonth

In today’s competitive therapeutic, diagnostic and medical device landscape, companies need to understand product value early on, and develop evidence to demonstrate value to all stakeholders. Market Access Consulting and Health Economics and Outcomes Research (HEOR) are more relevant than ever. Real-world evidence, patient-centered data and economic data are increasingly important to assist regulators and other stakeholders in understanding a product’s benefits, risks and value. Learn more: https://lnkd.in/eSaGp66s #MarketAccess #France #Pricing #Reimbursement #HEOR

Excellent interview about GLP-1 drugs Ozempic and Wegovy, with health researcher Ragan Chastain discussing what the research tells us and how the drug companies and media are distorting this information - using, it should be noted, some of the same tactics that Purdue used in pushing Oxycontin. There is a longer, paid version of this interview available too, but plenty of crucial insights in the free preview. #antidiet #disorderedeating #healthcare #wellness #dietitians #diabetes #research #media #healthliteracy

Revolutionising diabetes treatment through tradition African medicinal plants are showing promise in diabetes management, and can potentially offer safer, more accessible alternatives to synthetic drugs. With compounds demonstrating antidiabetic potential in studies, it’s time to bridge indigenous medicine and modern science. Clinical trials and further research could unlock new, sustainable treatments and improve global health. Explore the potential: https://buff.ly/49c8Umj #DiabetesManagement #MedicinalPlants #TraditionalMedicine #HealthInnovation #DrugDiscovery

In today’s competitive therapeutic, diagnostic and medical device landscape, companies need to understand product value early on, and develop evidence to demonstrate value to all stakeholders. Market Access Consulting and Health Economics and Outcomes Research (HEOR) are more relevant than ever. Real-world evidence, patient-centered data and economic data are increasingly important to assist regulators and other stakeholders in understanding a product’s benefits, risks and value. Learn more: https://lnkd.in/dycCxs-y #MarketAccess #France #Pricing #Reimbursement #HEOR #FortreaAlwaysOn

In today’s competitive therapeutic, diagnostic and medical device landscape, companies need to understand product value early on, and develop evidence to demonstrate value to all stakeholders. Market Access Consulting and Health Economics and Outcomes Research (HEOR) are more relevant than ever. Real-world evidence, patient-centered data and economic data are increasingly important to assist regulators and other stakeholders in understanding a product’s benefits, risks and value. Learn more: https://lnkd.in/eMQEuq-V #MarketAccess #France #Pricing #Reimbursement #HEOR

In today’s competitive therapeutic, diagnostic and medical device landscape, companies need to understand product value early on, and develop evidence to demonstrate value to all stakeholders. Market Access Consulting and Health Economics and Outcomes Research (HEOR) are more relevant than ever. Real-world evidence, patient-centered data and economic data are increasingly important to assist regulators and other stakeholders in understanding a product’s benefits, risks and value. Learn more: https://lnkd.in/gd9F4wNi #MarketAccess #France #Pricing #Reimbursement #HEOR

In today’s competitive therapeutic, diagnostic and medical device landscape, companies need to understand product value early on, and develop evidence to demonstrate value to all stakeholders. Market Access Consulting and Health Economics and Outcomes Research (HEOR) are more relevant than ever. Real-world evidence, patient-centered data and economic data are increasingly important to assist regulators and other stakeholders in understanding a product’s benefits, risks and value. Learn more: https://lnkd.in/gfxFNiGd #MarketAccess #France #Pricing #Reimbursement #HEOR